Product Description
A bispecific antibody directed against both the T-cell surface antigen CD3 and the tumor-associated antigen (TAA) cadherin-17 (CDH17), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CDH17/anti-CD3 bispecific antibody ARB202 binds to both CD3 on cytotoxic T lymphocytes (CTLs) and CDH17 on CDH17-expressing tumor cells, thereby crosslinking tumor cells and CTLs. This activates and redirects CTLs to CDH17-expressing tumor cells, which results in the CTL-mediated cell death of CDH17-expressing tumor cells. CDH17, a cell surface adhesion protein, is overexpressed in a variety of cancer cell types. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-cdh17-anti-cd3-bispecific-antibody-arb202)
Mechanisms of Action: CDH17 Inhibitor,CD3 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Arbele Pty Ltd
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|